WO2007138472A3 - Dérivés de la triazolopyridazine - Google Patents

Dérivés de la triazolopyridazine Download PDF

Info

Publication number
WO2007138472A3
WO2007138472A3 PCT/IB2007/001446 IB2007001446W WO2007138472A3 WO 2007138472 A3 WO2007138472 A3 WO 2007138472A3 IB 2007001446 W IB2007001446 W IB 2007001446W WO 2007138472 A3 WO2007138472 A3 WO 2007138472A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
formula
triazolopyridazine derivatives
relates
triazolopyridazine
Prior art date
Application number
PCT/IB2007/001446
Other languages
English (en)
Other versions
WO2007138472A2 (fr
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Hengmiao Cheng, Jingrong Jean Cui, Jacqui Elizabeth Hoffman, Lei Jia, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Bich Tran-Dube filed Critical Pfizer Prod Inc
Priority to EP07734734A priority Critical patent/EP2032578A2/fr
Priority to CA002651979A priority patent/CA2651979A1/fr
Priority to JP2009512702A priority patent/JP2009538899A/ja
Publication of WO2007138472A2 publication Critical patent/WO2007138472A2/fr
Publication of WO2007138472A3 publication Critical patent/WO2007138472A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou un de leurs sels pharmaceutiquement acceptable, dans laquelle R1, R2, R3 et R3' sont tels que définis ici. L'invention concerne également des compositions pharmaceutiques contenant les composés de formule (I) et des procédés de traitement des affections hyperprolifératives chez un mammifère par l'administration des composés de formule (I).
PCT/IB2007/001446 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine WO2007138472A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07734734A EP2032578A2 (fr) 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine
CA002651979A CA2651979A1 (fr) 2006-05-30 2007-05-18 Derives de la triazolopyridazine
JP2009512702A JP2009538899A (ja) 2006-05-30 2007-05-18 トリアゾロピリダジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80346906P 2006-05-30 2006-05-30
US60/803,469 2006-05-30

Publications (2)

Publication Number Publication Date
WO2007138472A2 WO2007138472A2 (fr) 2007-12-06
WO2007138472A3 true WO2007138472A3 (fr) 2008-02-07

Family

ID=38626862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001446 WO2007138472A2 (fr) 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine

Country Status (4)

Country Link
EP (1) EP2032578A2 (fr)
JP (1) JP2009538899A (fr)
CA (1) CA2651979A1 (fr)
WO (1) WO2007138472A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008277A (es) 2005-12-21 2009-03-04 Janssen Pharmaceutica Nv Triazolopiridazinas como moduladores de tirosina cinasa.
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
DK2081937T3 (da) * 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
EP2170337A4 (fr) 2007-06-28 2013-12-18 Abbvie Inc Nouvelles triazolopyridazines
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
KR20100128305A (ko) 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
WO2009126861A2 (fr) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés de triazolopyridine utiles en tant qu'inhibiteurs de dgat1
WO2009126624A1 (fr) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés triazolos utiles en tant qu'inhibiteurs de dgat1
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
CA2743000A1 (fr) * 2008-11-19 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibiteur a base de triazolothiadiazole de proteine kinase c-met
WO2010059771A1 (fr) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
KR20110113755A (ko) 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
CN102448969A (zh) * 2009-05-28 2012-05-09 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
PE20160588A1 (es) 2009-12-31 2016-07-09 Hutchison Medipharma Ltd Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588455B1 (fr) * 2010-07-02 2018-04-04 Gilead Sciences, Inc. Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CN104447867B (zh) * 2013-09-17 2017-12-26 江苏天士力帝益药业有限公司 一种噻吩并哌啶衍生物、制备方法及其应用
WO2015134854A2 (fr) * 2014-03-06 2015-09-11 Oyagen, Inc. Antagonistes à petites molécules obtenus par dimérisation de vif à titre d'agents anti-vih et pouvant être utilisés à titre d'agents thérapeutiques
PL224660B1 (pl) * 2014-07-23 2017-01-31 Inst Immunologii I Terapii Doświadczalnej Nowe analogi 1,2,4-triazoli i sposób otrzymywania analogów 1,2,4-triazoli
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012236A1 (fr) * 2000-08-04 2002-02-14 Bayer Cropscience Ag Triazolopyrid(az)ines substituees en tant qu'agents de traitement des vegetaux (herbicides)
WO2004058769A2 (fr) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs des proteine kinases
EP1481977A1 (fr) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Compose heterocyclique azote
WO2007064797A2 (fr) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012236A1 (fr) * 2000-08-04 2002-02-14 Bayer Cropscience Ag Triazolopyrid(az)ines substituees en tant qu'agents de traitement des vegetaux (herbicides)
EP1481977A1 (fr) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Compose heterocyclique azote
WO2004058769A2 (fr) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs des proteine kinases
WO2007064797A2 (fr) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUCEK, KARMEN ET AL: "Synthesis of novel [1,2,4]triazolo[4,3-b]pyridazines", ARKIVOC (GAINESVILLE, FL, UNITED STATES) [ONLINE COMPUTER FILE] , (5), 79-86 CODEN: AGFUAR URL: HTTP://WWW.ARKAT-USA.ORG/ARK/JOURNAL/VOLUME2/PART3/TISLER/MT-161/MT- 161.PDF, 2001, XP002459200 *
KOSARY ET AL.: "Preparation of New[1,2,4]Triazolo[4,3-b]pyridazines", PHARMAZIE, vol. 38, no. 6, 1983, pages 369 - 371, XP001536587 *

Also Published As

Publication number Publication date
JP2009538899A (ja) 2009-11-12
CA2651979A1 (fr) 2007-12-06
WO2007138472A2 (fr) 2007-12-06
EP2032578A2 (fr) 2009-03-11

Similar Documents

Publication Publication Date Title
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
CA2510853A1 (fr) Derives de pyrrolopyrimidine
WO2007061360A3 (fr) Nouveau composes
WO2007020213A3 (fr) Derives de thiazolylpiperidines
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2005080352A3 (fr) Derives de quinazoline et leur utilisation therapeutique
TW200728307A (en) Novel spirochromanone derivatives
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2007112000A3 (fr) Traitement de la douleur
TW200626158A (en) Naphthaline derivatives
WO2005075425A3 (fr) Derives de bisaryluree
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2006116148A3 (fr) Traitement de l'abus de substances toxiques
WO2006077024A3 (fr) Derives de 5-aminoindole
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2008006795A3 (fr) Composés d'indole
TW200639156A (en) New compounds
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2003074529A3 (fr) Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734734

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2651979

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009512702

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007734734

Country of ref document: EP